BioForm Medical, which markets a dermal filler to treat facial wrinkles and volume loss, priced 10 million shares at $8, a -20% discount to the midpoint of its proposed $9-$11 range. JP Morgan and Piper Jaffray managed the deal for the CA-based company. The stock is expected to begin trading on the NASDAQ on Wednesday under the ticker BFRM.
